A Platform for Comprehensive Genomic Profiling in Human Cancers and Pharmacogenomics Therapy Selection
- 877 Downloads
Recent innovations in next-generation sequencing (NGS) technologies have enabled comprehensive genomic profiling of human cancers in the clinical setting. The ability to profile has launched a worldwide trend known as precision medicine, and the fusion of genomic profiling and pharmacogenomics is paving the way for precision medicine for cancer. The profiling is coupled with information about chemical therapies available to patients with specific genotypes. As a result, the chemogenomic space in play is not only the standard chemical and genome space but also the mutational genome and chemical space. In this chapter, we introduce clinical genomic profiling using an NGS-based multiplex gene assay (OncoPrime™) at Kyoto University Hospital.
Key wordsMultiplex gene assay Next-generation sequencing Precision medicine Pharmacogenomics Clinical execution
- 22.Meric-Bernstam F, Johnson A, Holla V et al (2015) A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv098
- 23.Johnson DB, Dahlman KH, Knol J et al (2014) Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 19:616–622. https://doi.org/10.1634/theoncologist.2014-0011CrossRefPubMedPubMedCentralGoogle Scholar